The potential role of plasma miR‐155 and miR‐206 as circulatory biomarkers in inflammatory cardiomyopathy. (8th April 2021)

• Record Type: Journal Article
• Authors: Obradovic, Danilo; Rommel, Karl‐Philipp; Blazek, Stephan; Klingel, Karin; Gutberlet, Matthias; Lücke, Christian; Büttner, Petra; Thiele, Holger; Adams, Volker; Lurz, Philipp; Emrich, Fabian; Besler, Christian
• Is Part Of: ESC heart failure. Volume 8:Number 3(2021)
• Page Start: 1850
• Page End: 1860
• Publication Date: 2021-04-08
• Subjects: Inflammatory cardiomyopathy -- Dilated cardiomyopathy -- miRNA -- Endomyocardial biopsy -- Cardiovascular magnetic resonance imaging -- Lake Louise criteria; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.13304
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: Establishing a diagnosis of inflammatory cardiomyopathy (iCMP) by non‐invasive means remains challenging despite advances in cardiac magnetic resonance imaging. Previous studies suggested the involvement of microRNAs in the pathogenesis of iCMP. We examined the association of a predefined set of circulatory microRNAs with clinical characteristics of iCMP and evaluated their diagnostic performance in suspected iCMP. Methods and results: Eighty‐nine patients with clinical suspicion of iCMP were included in the analysis. All patients underwent cardiac catheterization with left ventricular endomyocardial biopsy, echocardiography, and cardiac magnetic resonance imaging applying the Lake Louise criteria (LLC). Plasma levels of miR‐21, miR‐126, miR‐133a, miR‐146b, miR‐155, and miR‐206 were determined using real‐time polymerase chain reaction. Based on immunohistological findings on endomyocardial biopsy, iCMP was diagnosed in 67% of study participants ( n = 60). Plasma levels of miR‐155 and miR‐206 were significantly increased in patients with iCMP as compared with patients with dilated cardiomyopathy ( P = 0.008 and P = 0.009, respectively). In receiver operating characteristic curve analysis, miR‐155 and miR‐206 demonstrated superior diagnostic performance for iCMP (0.68 and 0.67, respectively) compared with LLC [area under the curve (AUC) 0.60], Troponin T (AUC 0.51), and N‐terminal pro‐brain natriuretic peptide (AUC 0.51). While baseline miR‐155 and miR‐206 plasma levels were predictive for biopsy‐proven iCMP (odds ratio = 2.61, 95% confidence interval = 1.28–5.31, P = 0.008 and odds ratio = 2.65, 95% confidence interval = 1.27–5.52, P = 0.009) on univariate logistic regression analysis, the presence of positive LLC, high baseline C‐reactive protein, or presence of clinical symptoms and signs of viral infection failed to predict iCMP ( P > 0.05, respectively). Conclusions: The present data suggest that plasma levels of miR‐206 and miR‐155 are potential novel biomarkers for confirming the diagnosis of iCMP.